Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer

被引：0
|
作者：
Leyvraz, S. [1 ]
Hong, D. S. [2 ]
Shen, L. [3 ]
van Tilburg, C. M. [4 ,5 ]
Tan, D. S. W. [6 ]
Kummar, S. [7 ]
Lin, J. J. [8 ,9 ]
Doz, F. [10 ,11 ]
McDermott, R. [12 ,13 ]
Albert, C. M. [14 ,15 ]
Berlin, J. [16 ]
Bielack, S. [17 ]
Lassen, U. N. [18 ]
Tahara, M. [19 ]
Norenberg, R. [20 ]
Shurshalina, A. [21 ]
Fellous, M. [22 ]
Nogai, H. [22 ]
Xu, R. [23 ]
Laetsch, T. W. [24 ]
Drilon, A. [25 ,26 ]
机构：
[1] Charite Comprehens Canc Ctr, Berlin, Germany
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China
[4] Heidelberg Univ Hosp, Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany
[5] German Canc Res Ctr, Heidelberg, Germany
[6] Natl Canc Ctr Singapore, Singapore, Singapore
[7] OHSU, Knight Canc Inst, Portland, OR USA
[8] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[9] Harvard Med Sch, Boston, MA 02115 USA
[10] Inst Curie, Paris, France
[11] Univ Paris, Paris, France
[12] St Vincents Univ Hosp, Dublin, Ireland
[13] Canc Trials Ireland, Dublin, Ireland
[14] Seattle Childrens Hosp, Seattle, WA USA
[15] Univ Washington, Sch Med, Seattle, WA USA
[16] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[17] Klinikum Stuttgart Olgahosp, Stuttgart, Germany
[18] Rigshosp, Dept Oncol, Copenhagen, Denmark
[19] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[20] Chrestos Concept GmbH & Co KG, Essen, Germany
[21] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[22] Bayer HealthCare Pharmaceut Inc, Basel, Switzerland
[23] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[24] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[25] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[26] Weill Cornell Med Coll, New York, NY USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V101
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [41] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Lassen, U. N.
    Albert, C. M.
    Kummar, S.
    van Tilburg, C. M.
    Dubois, S. G.
    Geoerger, B.
    Mascarenhas, L.
    Federman, N.
    Schilder, R. J.
    Doz, F.
    Berlin, J. D.
    Oh, D-Y.
    Bielack, S. S.
    McDermott, R.
    Tan, D. S.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Drilon, A.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2018, 29 : 133 - 133
  • [42] Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
    Shen, L.
    Hong, D. S.
    Tahara, M.
    Baik, C. S.
    Bauman, J. R.
    Gilbert, J.
    Brose, M. S.
    Grilley-Olson, J. E.
    Patil, T.
    McDermott, R. S.
    Raez, L. E.
    Johnson, J. M.
    Norenberg, R.
    Dima, L.
    Mussi, C. E.
    Le, X.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S1521 - S1522
  • [43] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Tan, D. S. W.
    Lassen, U. N.
    Albert, C. M.
    Kummar, S.
    van Tilburg, C.
    Dubois, S. G.
    Geoerger, B.
    Mascarenhas, L.
    Federman, N.
    Basu-Mallick, A.
    Doz, F.
    Berlin, J. D.
    Oh, D-Y.
    Bielack, S.
    McDermott, R.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Drilon, A.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
    Waguespack, Steven G.
    Drilon, Alexander
    Lin, Jessica J.
    Brose, Marcia S.
    McDermott, Ray
    Almubarak, Mohammed
    Bauman, Jessica
    Casanova, Michela
    Krishnamurthy, Anuradha
    Kummar, Shivaani
    Leyvraz, Serge
    Oh, Do-Youn
    Park, Keunchil
    Sohal, Davendra
    Sherman, Eric
    Norenberg, Ricarda
    Silvertown, Josh D.
    Brega, Nicoletta
    Hong, David S.
    Cabanillas, Maria E.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 186 (06) : 631 - 643
  • [45] Efficacy of larotrectinib in TRK fusion cancer in adults and children
    Blattmann, C.
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 154 - 155
  • [46] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Blattmann, C.
    Albert, C. M.
    Kummar, S.
    van Tilburg, C. M.
    Dubois, S. G.
    Geoerger, B.
    Mascarenhas, L.
    Federman, N.
    Schilder, R. J.
    Doz, F.
    Berlin, J. D.
    Oh, D. -Y.
    Bielack, S. S.
    McDermott, R.
    Tan, D. S.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Drilon, A.
    Hong, D. S.
    Lassen, U. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 27 - 27
  • [47] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Drilon, A.
    Shen, L.
    van Tilburg, C.
    Doz, F.
    Tan, D. S. W.
    Lin, J. J.
    Kummar, S.
    Lassen, U. N.
    McDermott, R. S.
    Dierselhuis, M. P.
    Albert, C. M.
    Nagasubramanian, R.
    Watt, T.
    Patil, T.
    Burcoveanu, D-I.
    Norenberg, R.
    Brega, N.
    Laetsch, T. W.
    Xu, R-H.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S470 - S470
  • [48] Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
    Drilon, Alexander E.
    Lin, Jessica Jiyeong
    Kummar, Shivaani
    Tan, Daniel Shao-Weng
    Patel, Jyoti D.
    Lassen, Ulrik Niels
    Leyvraz, Serge
    Moreno, Victor
    Rosen, Lee S.
    Solomon, Benjamin Maurice
    Yachnin, Jeffrey
    Liu, Yongmei
    Dai, Ming-Shen
    Norenberg, Ricarda
    Fellous, Marc Mardoche
    Mussi, Chiara Erminia
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
    Shen, Lin
    Andre, Thierry
    Chung, Hyun Cheol Cheol
    Deeken, John F.
    Garralda, Elena
    Italiano, Antoine
    Leyvraz, Serge
    Liu, Tianshu
    Burcoveanu, Domnita-Ileana
    Grugel, Robin
    Mussi, Chiara E.
    Xu, Rui-Hua
    Hong, David S.
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 109 - 109
  • [50] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
    Drilon, A.
    Lin, J.
    Lassen, U.
    Leyvraz, S.
    Liu, Y.
    Patel, J.
    Rosen, L.
    Solomon, B.
    Norenberg, R.
    Dima, L.
    Brega, N.
    Shen, L.
    Moreno, V.
    Kummar, S.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1125 - S1126
12345